Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-Overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone.

Trial Profile

A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-Overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BL 1020 (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms EAGLE
  • Most Recent Events

    • 09 Oct 2012 Results from a reanalysis of the data assessing the effects of circadian rhythm on cognitive function were reported in a BioLineRx media release.
    • 27 Sep 2011 Results will be presented at the 3rd European Conference on Schizophrenia Research (ECSR).
    • 23 Sep 2009 Status changed from active, no longer recruiting to completed, based on BioLineRx media release report of final results.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top